References
- Adlam VJ, Harrison JC, Porteous CM, et al. (2005). Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19:1088–95
- Armstrong JS. (2007). Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 151:1154–65
- Boddapati SV, D'souza GG, Erdogan S, et al. (2008). Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559–63
- Boddapati SV, Tongcharoensirikul P, Hanson RN, et al. (2005). Mitochondriotropic liposomes. J Liposome Res 15:49–58
- Colles SM, Chisolm GM. (2000). Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res 41:1188–98
- D'souza GG, Rammohan R, Cheng SM, et al. (2003). DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 92:189–97
- Flierl A, Jackson C, Cottrell B, et al. (2003). Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol Ther 7:550–7
- Fuller N, Rand RP. (2001). The influence of lysolipids on the spontaneous curvature and bending elasticity of phospholipid membranes. Biophys J 81:243–54
- Golan DE, Brown CS, Cianci CM, et al. (1986). Schistosomula of Schistosoma mansoni use lysophosphatidylcholine to lyse adherent human red blood cells and immobilize red cell membrane components. J Cell Biol 103:819–28
- Jiang J, Stoyanovsky DA, Belikova NA, et al. (2009). A mitochondria-targeted triphenylphosphonium-conjugated nitroxide functions as a radioprotector/mitigator. Radiat Res 172:706–17
- Lin MT, Beal MF. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–95
- Murakami M, Cabral H, Matsumoto Y, et al. (2011). Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med 3:64ra2
- Murphy MP, Smith RA. (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47:629–56
- Patel NR, Hatziantoniou S, Georgopoulos A, et al. (2010). Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res 20:244–9
- Rajendran L, Knolker HJ, Simons K. (2010). Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 9:29–42
- Ross MF, Prime TA, Abakumova I, et al. (2008). Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J 411:633–45
- Savic R, Luo L, Eisenberg A, Maysinger D. (2003). Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300:615–18
- Smith RA, Porteous CM, Gane AM, Murphy MP. (2003). Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 100:5407–12
- Solomon MA, Shah AA, D'souza GG. (2013). In vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel. Mitochondrion 13:464–72
- Traikia M, Marbeuf-Gueye C, Hantz E, Le Moyec L. (2005). Impact of exogenous lysolipids on sensitive and multidrug resistant K562 cells: 1H NMR studies. Chem Biol Interact 151:83–94
- Van Der Luit AH, Budde M, Ruurs P, et al. (2002). Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 277:39541–7
- Wallace DC. (1999). Mitochondrial diseases in man and mouse. Science 283:1482–8
- Yamada Y, Akita H, Kamiya H, et al. (2008). MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778:423–32